901.19
0.79%
+7.05
Pre-market:
901.13
-0.06
-0.01%
Regeneron Pharmaceuticals, Inc. stock is currently priced at $901.19, with a 24-hour trading volume of 462.03K.
It has seen a +0.79% increased in the last 24 hours and a -6.56% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $895.2 pivot point. If it approaches the $905.8 resistance level, significant changes may occur.
Regeneron Pharmaceuticals, Inc. Stock (REGN) Financials Data
Regeneron Pharmaceuticals, Inc. (REGN) Revenue 2024
REGN reported a revenue (TTM) of $13.12 billion for the quarter ending December 31, 2023, a +7.76% rise year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Net Income 2024
REGN net income (TTM) was $3.95 billion for the quarter ending December 31, 2023, a -8.87% decrease year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow 2024
REGN recorded a free cash flow (TTM) of $3.67 billion for the quarter ending December 31, 2023, a +7.93% increase year-over-year.
Regeneron Pharmaceuticals, Inc. (REGN) Earnings per Share 2024
REGN earnings per share (TTM) was $34.75 for the quarter ending December 31, 2023, a -9.13% decline year-over-year.
Regeneron Pharmaceuticals, Inc. Stock (REGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
McCourt Marion | EVP Commercial |
Apr 01 '24 |
Sale |
964.73 |
250 |
241,182 |
13,181 |
RYAN ARTHUR F | Director |
Apr 01 '24 |
Sale |
962.53 |
100 |
96,253 |
18,182 |
MURPHY ANDREW J | EVP Research |
Mar 14 '24 |
Sale |
956.47 |
5,783 |
5,531,290 |
48,306 |
MURPHY ANDREW J | EVP Research |
Mar 13 '24 |
Option Exercise |
399.66 |
20,000 |
7,993,200 |
68,306 |
McCourt Marion | EVP Commercial |
Mar 01 '24 |
Sale |
967.50 |
358 |
346,365 |
13,431 |
RYAN ARTHUR F | Director |
Mar 01 '24 |
Sale |
982.05 |
100 |
98,205 |
18,282 |
SING GEORGE L | Director |
Feb 26 '24 |
Option Exercise |
413.33 |
1,000 |
413,330 |
26,849 |
Bassler Bonnie L | Director |
Feb 26 '24 |
Option Exercise |
391.92 |
854 |
334,700 |
2,236 |
SING GEORGE L | Director |
Feb 26 '24 |
Sale |
992.50 |
1,000 |
992,500 |
26,349 |
LAROSA JOSEPH J | EVP General Counsel and Secret |
Feb 26 '24 |
Sale |
990.00 |
1,000 |
990,000 |
36,543 |
Regeneron Pharmaceuticals, Inc. Stock (REGN) Latest News
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Benzinga
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Zacks Investment Research
Why Regeneron (REGN) Could Beat Earnings Estimates Again
Zacks Investment Research
Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea
Zacks Investment Research
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
Benzinga
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Cap:
|
Volume (24h):